PACIFIC-AF is a multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding phase 2 study comparing the safety of the oral FXIa inhibitor asundexian with apixaban in patients with atrial fibrillation. It was a pleasure to speak with Prof. Manesh Patel (Duke University, Durham, NC) who gives an overview on asendexian; its future in the treating paradigm for atrial fibrillation (AF) and also the benefits of this drug. In addition, he also discusses the PACIFIC-AF study.
Questions:
- Could you tell us a little about asundexian and its potential advantages compared to the currently available non-vitamin K oral anticoagulants? (00:17)
- What were the aims and design of the PACIFIC-AF study? (02:17)
- How did the efficacy and safety of asundexian compare with that of apixaban? (03:44)
- What will be the next steps in the clinical development of asundexian? (05:08)
- Where do you see asundexian sitting in the treatment paradigm for AF? (05:58)
Disclosures: Manesh Patel is a consultant for Bayer, Hearflow, Janssen and Novartis and discloses grant/research support from Bayer, Heartflow, Janssen and NIH.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
